Crescent Grove Advisors’s Aratana Therapeutics, Inc. PETX Stock Holding History

Crescent Grove Advisors’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-17,975	Closed	-$93K	–	170
2019 Q2	$93K	Hold	17,975	–	–	0.02%	155
2019 Q1	$65K	Hold	17,975	–	–	0.01%	148
2018 Q4	$110K	Hold	17,975	–	–	0.02%	149
2018 Q3	$105K	Hold	17,975	–	–	0.02%	138
2018 Q2	$76K	Hold	17,975	–	–	0.02%	138
2018 Q1	$79K	Hold	17,975	–	–	0.02%	142
2017 Q4	$95K	Sell	17,975 -14,275	-44%	-$87.3K	0.02%	137
2017 Q3	$198K	Hold	32,250	–	–	0.05%	129
2017 Q2	$233K	Buy	+32,250	New	+$198K	0.07%	124

Other funds holding PETX

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Crescent Grove Advisors's PETX Position: Q3 2019 in Review

Crescent Grove Advisors sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 17,975 shares — an estimated $93K sold.

Crescent Grove Advisors first reported a position in PETX in Q2 2017 and held it in 9 quarters. The position peaked at $233K in Q2 2017. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

Crescent Grove Advisors reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Crescent Grove Advisors sold 17,975 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $93K.
Crescent Grove Advisors first reported a position in Aratana Therapeutics, Inc. in Q2 2017 and held it in 9 quarters.
Crescent Grove Advisors's Aratana Therapeutics, Inc. position peaked at $233K in Q2 2017.
2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on Crescent Grove Advisors's 13F filing for Q3 2019, filed 31 Oct 2019.